Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2007
12/21/2007WO2007146768A2 Compounds for the treatment of metabolic disorders
12/21/2007WO2007146761A2 Diaryl pyrimidinones and related compounds
12/21/2007WO2007146759A2 Novel mch receptor antagonists
12/21/2007WO2007146758A2 Novel mch receptor antagonists
12/21/2007WO2007146730A2 Deacetylase inhibitor therapy
12/21/2007WO2007146715A1 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
12/21/2007WO2007146712A2 Therapy using cytokine inhibitors
12/21/2007WO2007146695A1 Acyclic oximyl hepatitis c protease inhibitors
12/21/2007WO2007146684A1 Ophthalmic compositions comprising a branched, glycerol compound and a cationic antimicrobial
12/21/2007WO2007146602A1 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
12/21/2007WO2007146553A2 N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2h)-pyrazineacetamide
12/21/2007WO2007146440A2 Glucan preparations
12/21/2007WO2007146438A1 Hif hydroxylase inhibitors for treatment of anemia of cancer
12/21/2007WO2007146417A2 Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity
12/21/2007WO2007146416A2 Glucan preparations
12/21/2007WO2007146313A1 Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
12/21/2007WO2007146311A2 Compositions and methods for protecting newborn lung development with ethyl nitrite
12/21/2007WO2007146306A2 Methods and compositions for improving cognitive function
12/21/2007WO2007146261A2 Biomolecule-linked biomimetic scaffolds
12/21/2007WO2007146248A2 Stable laquinimod preparations
12/21/2007WO2007146234A2 Solid oral dosage form containing an enhancer
12/21/2007WO2007146230A2 Non-nucleoside reverse transcriptase inhibitors
12/21/2007WO2007146225A2 Heterocyclic aspartyl protease inhibitors
12/21/2007WO2007146224A2 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
12/21/2007WO2007146202A2 Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
12/21/2007WO2007146178A1 A method of reducing amyloid-beta peptide levels using a bisdioxopiperazine
12/21/2007WO2007146174A2 Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
12/21/2007WO2007146167A1 Compositions and methods relating to novel compounds and targets thereof
12/21/2007WO2007146136A2 Ophthalmic compositions for treating ocular hypertension
12/21/2007WO2007146124A2 Deuterated tadalafil derivatives
12/21/2007WO2007146122A2 Tetrahydropyrido[3,4-d]pyrimidines and related analogues
12/21/2007WO2007146116A2 Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
12/21/2007WO2007146088A1 Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof
12/21/2007WO2007146087A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE
12/21/2007WO2007146086A1 Creatine prodrugs, compositions and uses thereof
12/21/2007WO2007146085A2 Creatine phosphate prodrugs, compositions and uses thereof
12/21/2007WO2007146073A2 Method for enhancing cognitive function
12/21/2007WO2007146068A2 Controlled release alfuzosin hydrochloride formulation
12/21/2007WO2007146066A2 Novel piperazines, pharmaceutical compositions and methods of use thereof
12/21/2007WO2007146039A2 Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
12/21/2007WO2007146012A1 Treatment of periodontal disease associated with increased c-reactive protein levels
12/21/2007WO2007146006A2 Sustained release oxycodone composition with acrylic polymer and a surfactant
12/21/2007WO2007145993A2 Modified compositions and methods for enhancing brain function
12/21/2007WO2007145991A2 Anti-inflammatory and analgesic compositions and related methods
12/21/2007WO2007145957A1 Inhibitors of janus kinases
12/21/2007WO2007145922A2 Benzazepinones as sodium channel blockers
12/21/2007WO2007145921A1 Imidazopyrazines as protein kinase inhibitors
12/21/2007WO2007145888A2 Oxime derivatives as inhibitors of macrophage migration inhibitory factor
12/21/2007WO2007145874A1 Anti-nicotine treatment comprising use of three anticholinergic agents
12/21/2007WO2007145868A1 Treating cystic fibrosis with antibiotics via an aerosol drug
12/21/2007WO2007145866A1 Treating cystic fibrosis with antibiotics via a swirler delivery
12/21/2007WO2007145704A2 Gemcitabine combination therapy
12/21/2007WO2007145682A1 Oral dtpa for radionuclide chelation
12/21/2007WO2007145663A1 Large-particle cyclodextrin inclusion complexes and methods of preparing same
12/21/2007WO2007145656A2 Cefquinome compositions and methods of their use
12/21/2007WO2007145571A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
12/21/2007WO2007145570A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
12/21/2007WO2007145569A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
12/21/2007WO2007145568A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
12/21/2007WO2007145563A1 Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
12/21/2007WO2007145519A1 Milk fever
12/21/2007WO2007145455A1 Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof
12/21/2007WO2007145453A1 High throughput screening method of binding inhibitor between caspase3 and xiap, and binding inhibitor screened thereby
12/21/2007WO2007145405A1 A cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof
12/21/2007WO2007145365A1 Therapeutic agent for cancer and method for screening for the same
12/21/2007WO2007145356A1 α-GLUCOSIDASE INHIBITOR, INHIBITOR FOR BLOOD GLUCOSE LEVEL ELEVATION AND FUNCTIONAL FOOD CONTAINING TRICAFFEOYLALDARIC ACID AND METHOD FOR PRODUCING TRICAFFEOYLALDARIC ACID
12/21/2007WO2007145326A1 Method for determination of inflammatory disease
12/21/2007WO2007145308A1 Agent for prevention and/or treatment of glomerulopathy
12/21/2007WO2007145282A1 Therapeutic or prophylactic agent for allergic dermatitis
12/21/2007WO2007145253A1 NF-ϰB ACTIVATION INHIBITOR
12/21/2007WO2007145239A1 Anti-fatigue agent containing amino acid composition
12/21/2007WO2007145191A1 Coated tablet
12/21/2007WO2007144985A1 Use of rpn2 gene expression inhibitor
12/21/2007WO2007144943A1 Composition for enhancing immune function
12/21/2007WO2007144902A1 Chewable bilayer tablet formulation
12/21/2007WO2007144900A2 Carvedilol phosphate sesquihydrate
12/21/2007WO2007144876A1 Methods for treating cancer
12/21/2007WO2007144669A1 Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
12/21/2007WO2007144668A2 Process for the preparation of s-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
12/21/2007WO2007144639A1 2 -oxybenzamide derivatives as parp inhibitors
12/21/2007WO2007144637A1 2 -oxyheteroarylamide derivatives as parp inhibitors
12/21/2007WO2007144628A1 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression
12/21/2007WO2007144625A1 2-oxo-2h-chromene compounds
12/21/2007WO2007144621A2 Protection against and treatment of age related macular degeneration
12/21/2007WO2007144613A1 Antimicrobial composition
12/21/2007WO2007144604A1 Stable aerosol pharmaceutical formulations
12/21/2007WO2007144579A1 N-oxides of diarylurea derivatives and their use as chk1 inhibitors for the treatment of cancer
12/21/2007WO2007144571A1 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid
12/21/2007WO2007144530A2 Free-radical-scavenger cosmetic composition
12/21/2007WO2007144501A2 Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension
12/21/2007WO2007144423A1 Antitumoral dihydropyran-2-one compounds
12/21/2007WO2007144422A2 Combination preparations comprising bifeprunox and l-dopa
12/21/2007WO2007144421A1 Combination preparations comprising slv308 and a l-dopa
12/21/2007WO2007144418A1 Oral pharmaceutical composition of a poorly water-soluble active substance
12/21/2007WO2007144400A1 Benzylpiperazine derivatives as motilin receptor antagonists
12/21/2007WO2007144394A2 Pharmaceutical use of substituted piperidine carboxamides
12/21/2007WO2007144390A1 Use of a p38 kinase inhibitor for treating psychiatric disorders
12/21/2007WO2007144384A1 Pyrazolopyrimidones
12/21/2007WO2007144381A1 Composition for the relief of joint pain
12/21/2007WO2007144379A1 Bicyclic compounds useful as cathepsin s inbhibitors
1 ... 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 ... 7860